US Tariff Policy Shifts Dramatically Impact India Trade Pharmaceutical Exports Face 100 Percent Duties

Welcome back to India Tariff News and Tracker. I'm your host, and we've got significant developments to cover today regarding how U.S. tariff policy is reshaping trade with India. The landscape has shifted dramatically since the Supreme Court struck down the International Emergency Economic Powers Act tariffs back in February. What replaced them is a temporary 10 percent global Section 122 tariff that's now in effect through late July, according to trade policy updates from C.H. Robinson's freight market analysis. But here's what matters for India specifically: the administration is building something much more durable underneath. The U.S. Trade Representative has launched sweeping Section 301 investigations explicitly designed to replace the IEEPA regime with firmer legal footing. One investigation covers forced labor enforcement failures across 60 countries, which directly impacts India given ongoing scrutiny of labor practices in Indian manufacturing sectors. The other targets structural excess industrial capacity in 16 countries plus the EU. These investigations could reshape tariff rates dramatically when they conclude before late July. For pharmaceutical imports specifically, India's exposure is substantial. On April 2nd, President Trump issued a proclamation imposing Section 232 tariffs on patented pharmaceuticals reaching up to 100 percent. India supplies significant quantities of active pharmaceutical ingredients to the United States, and these tariffs could fundamentally alter that supply chain. The baseline rate is 100 percent, though there are company-specific exclusions and reductions for those committing to onshoring. Tariffs take effect July 31st for larger companies and September 29th for others. Indian pharmaceutical manufacturers should note that tariffs for countries with existing trade frameworks get preferential treatment, and India currently doesn't have that status, meaning Indian imports face the full 100 percent baseline unless specific exclusions apply. The C.H. Robinson analysis notes that Section 301 investigations will likely create country-specific tariff regimes. India's classification in these investigations remains unclear, but the forced labor investigation is particularly relevant given supply chain audits affecting Indian manufacturers across textiles, agriculture, and industrial goods. What listeners need to understand is that we're in a transition period. The temporary Section 122 tariff is a bridge until Section 301 investigations conclude. For Indian exporters and American importers of Indian goods, this means two critical things: first, tariff rates could spike significantly when Section 301 remedies are announced; second, the pharmaceutical sector faces immediate rate changes in less than four months. We'll continue tracking these developments as the investigation hearings begin in late April and early May. Thank you for tuning in to India Tariff News and Tracker. Make sure to subscribe so you don' This content was created in partnership and with the help of Artificial Intelligence AI.